The 13-valent pneumococcal conjugate (PCV13, Prevenar 13®, Pfizer Inc., NY, USA) was
developed as a successor to the currently registered 7-valent pneumo coccal conjugate …

The introduction of a 7-valent pneumococcal conjugate vaccine (PCV-7) into the routine
childhood vaccination schedule has been shown to be effective in preventing invasive …

The thirteen valent pneumococcal conjugate vaccine (PCV13, Prevenar 13Ô) is the broader
coverage successor to the highly effective seven valent vaccine (PCV7, PrevenarÔ) which …

Pneumococcal disease remains a global problem despite the availability of effective
conjugate vaccines. The 13-valent pneumococcal conjugate vaccine (PCV13) extends the …

13-valent pneumococcal conjugate vaccine (PCV13) was compared to PCV7 in infants
administered 4 doses. For the 7 common serotypes, PCV13-and PCV7-elicited responses …

One of the great success stories in pneumococcal vaccines is the 7-valent conjugated
pneumococcal vaccine (PCV-7); and with wider coverage, the broad prevention it offers …

Background: Meta-analyses enable summarization and interpretation of data across clinical
trials. When applied to safety data they allow for detection of rare events. Recently, a 13 …

Pneumococcal disease is complex with many disease manifestations. Streptococcus
pneumoniae causes a variety of illnesses, from acute otitis media to clinical pneumonia and …

A 13-valent pneumococcal conjugate vaccine (PCV13), developed with the same chemistry
used for the 7-valent PCV vaccine (PCV7) and with the goal of expanding serotype …

Pneumococcal disease is a leading cause of childhood morbidity and mortality globally,
causing an estimated 0.7--1.0 million deaths annually among children aged< 5 years. A …